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Abstract
Background: Using blood-based biomarkers such as microRNAs (miRNAs) may allow
particularly effective and minimally invasive diagnosis and treatment of endometriosis.
Objective: We evaluated the differential expression of circulating miRNA-185-5p (miR-
185-5p), vascular endothelial growth factor (VEGF), and platelet-derived growth factor
(PDGF) target genes between endometriosis and healthy women.
Materials and Methods: 25 women with a history of endometriosis (grad III-IV)
diagnosed by laparoscopy as the case group and 25 women without endometriosis
underwent laparoscopy for ovarian cysts or pelvic pain as the control group were
enrolled in this case-control study. Blood samples were obtained, and total RNA was
used for high-throughput small RNA sequencing, and this was confirmed by means of
quantitative real-time polymerase chain reaction (qRT-PCR).
Results: miRNA expression profiling using non-coding RNA sequencing revealed that
one miRNA including miR-185-5p was significantly down-regulated in the case group
compared with the controls. The qRT-PCR results showed significant downregulation of
the expression level of miR-185-5p (p < 0.01) in the plasma of the case group. Receiver
operating characteristic (ROC) curve analysis showed the area of miR-185-5p under
the ROC curve for endometriosis diagnosis was 0.919 (p < 0.001). The RT-PCR results
demonstrated that there was no significant difference in the expression of VEGF and
PDGF mRNA of blood samples in the cases compared to the control group (PDGF, p =
0.09 and VEGF, p = 0.36).
Conclusion: The low expression of miR-185-5p in the plasma of women with
endometriosis could be employed as an important non-invasive biomarker for early
detection and screening of endometriosis by blood samples.
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1. Introduction
The human endometrium is an angiogenic
tissue with a large number of endometrial stem
cells and notable remodeling potential and
is a major source of angiogenesis activators,
which are produced by endometrial tissue
(1). The important role of angiogenesis and
angiogenic factors in the pathophysiology of
endometriosis has been confirmed. Angiogenesis
is an essential process in the growth, persistence,
andmetastases of solid tumors (2, 3). Angiogenesis
is balanced by proangiogenic and antiangiogenic
mediators and is controlled by angiogenesis-
related factors, including vascular endothelial
growth factor (VEGF), platelet-derived growth
factor (PDGF), fibroblast growth factor (FGF),
tumor necrosis factor-alpha, transforming growth
factor-beta, and the angiopoietins (4, 5). Many
types of cells, including fibroblasts, endothelial
cells, platelets, inflammatory cells, smooth
muscle cells, and tumor cells, produce and
release these growth factors (6). The most
potent factor for induction of angiogenesis
is hypoxia, which induces the expression of
VEGF. The VEGF family in humans consists
of five members. Among them, VEGF-A and
VEGF-C are expressed by the endometrium and
VEGF receptor tyrosine kinases, VEGFRs 1 (Flt-1),
VEGFR-2 (KDR, Flk-1), and VEGFR-3 (Flt-4), which
are exclusively expressed in endothelial cells,
hematopoietic stem cells, and tumor cells (7,
8).
In addition to VEGF, PDGF has a critical
role in angiogenesis and could be essential
during vascularization. Although the fundamental
molecular mechanisms of PDGF in angiogenesis
have not yet been precisely defined, PDGF
has attracted much attention from researchers
from diverse backgrounds. PDGF and its specific
receptors are expressed by natural and tumor
cells and have been considered as an anti-
angiogenic target for the treatment of solid
tumors (9). The PDGF receptor tyrosine kinases,
which are known as the α and β subunits,
disrupt PDGF-B/𝛽 signaling and are associatedwith
significant vascular abnormalities in physiologic
and pathologic angiogenesis (10, 11).
Recently, it has been said that microRNAs
(miRNAs) are commonly dysregulated in
endometriosis. Emerging data show that abnormal
miRNA expression in relation to endometriosis
may facilitate the development and progression
of endometriosis by controlling the proliferation,
apoptosis, migration, invasion, and estradiol signal
transduction in endometriotic cells (3-5).
Little is known about the pathophysiological
significance of miRNA-185 (miR-185) in
endometriosis. To investigate the molecular
mechanisms by which miR-185 may participate in
endometriosis, its target genes were searched.
Among them, it was found that there was a highly
conserved miR-185 responsive element in the 3’-
untranslated region (3’-UTR) of VEGF-A and PDGF.
It has been reported that VEGF-A is an important
angiogenesis regulator that is highly expressed
in tumor tissues such as endometrial tissue, and
it is proposed that it is closely associated with
aggressive tumor features (12, 13).
We speculate that VEGFA may be the target
gene of miR-185. Considering the importance and
the role of miRNAs in pathogenesis as well as the
diagnosis and progression of various diseases, and
the importance of angiogenesis in the progression
of endometriosis, the present study evaluated the
differential expression of circulating miR-185-5p
and predicted the downstream VEGF and PDGF
target genes between endometriosis women
and healthy controls using real-time quantitative
reverse transcription polymerase chain reaction
(RT-PCR) to provide evidence of the value of
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miR-185-5p as a new diagnostic biomarker for
endometriosis.
In this study, the expression pattern of miR-
185 and its target genes VEGF-A and PDGF were
evaluated and compared in whole blood from
women with and without endometriosis.
2. Materials and Methods
2.1. Participants
25 women aged 18-44 yr old with a history
of endometriosis (grade III-IV) diagnosed by
laparoscopy as the case group and 25 women in
the same age range without endometriosis who
underwent laparoscopy for ovarian cysts or pelvic
pain, referred to Yazd Khatam-ol-Anbia Clinic of
Shahid Sadoughi University of Medical Science,
Yazd, Iran, as the control group were enrolled
in this cross-sectional study from March 2018
to March 2019. The diagnosis of endometriosis
was confirmed histologically, and the severity
of endometriosis was classified based on the
American Society for Reproductive Medicine
(ASRM; 1997) revised classification system (14). In
all women with endometriosis, mRNA and miRNA
expression of whole blood (WB) and sera were
evaluated by real-time quantitative RT-PCR.
2.2. Blood, plasma, and sample
preparation and RNA extraction
10 ml venous blood samples were collected in
five ethylenediaminetetraacetic acid tubes. Then,
one tube was diluted (1:1) with sterile phosphate-
buffered saline. Next, standard Ficoll-Hypaque
density gradient centrifugation was performed to
isolate PBMCs, and plasma was saved for further
analysis (15). Two tubes were centrifuged for 15
min at 4000 rpm, and the isolated plasma was
saved. Total RNA was isolated from whole blood
using the QIAamp RNA Blood Mini Kit (QIAGEN,
Germany) with the addition of an on-column DNase
I digestion to remove any possible remnants of
genomic DNA according to the manufacturer’s
instructions (16, 17). In addition, total miRNA was
isolated from the plasma using the QIAamp
miRNA Plasma/Serum Mini kit (QIAGEN, Germany)
according to the manufacturer’s protocol. The
quantity and concentration of extracted RNA
were determined using the NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA). The quality of RNA
samples was also assessed by 1.5% agarose
gel electrophoresis.
2.3. miRNA sequencing
The RNA samples were sent to the Dr. Faghihi’s
Medical Genetic Center (Shiraz, Iran) for whole-
genome miRNA sequencing. The Persian Bayan
Gene conducted the miRNA profiling using an
Illumina HiSeq sequencer. Illumina TruSeq Small
RNA sample prep kits (Illumina, USA) were used to
prepare miRNA libraries.
2.4. Reverse transcription and
expression analysis
RevertAid Reverse Transcriptase (ThermoFisher
Scientific) was used to synthesize single-stranded
complementary DNA (cDNA) 1 µg of total RNA
following the manufacturer’s instructions (18). The
cDNA synthesis formicroRNAwas performed using
the polyadenylation method. In this method, poly-
A polymerase was applied to the extracted RNA
to be polyadenylated and then this RNA used as a
template to synthesize the first-strand cDNA. These
cDNAs were then diluted to a final concentration of
400 ng/µl for using in the quantitative real-time RT-
PCR (qRT-PCR) reactions.
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2.5. miRNA sequencing data analysis
For bioinformatics analysis, miRBase was used
as a reference library (http://www.mirbase.org/ ftp:
//mirbase.org/pub/mirbase/CURRENT/README).
Low-quality reads were filtered out, while the
qualified reads were strictly drawn to all known
mature and precursor sequences, in addition to
the human genomes. The bioinformatics software
was used to analyze the differentially expressed
miRNAs between the endometriosis and control
subjects. The miRNAs with a p-value < 0.05 were
considered significantly differential.
2.6. Real-time RT-PCR analysis
StepOnePlus Real-Time PCR system (Applied
Biosystems, USA) was used to perform Real-
time RT-PCRs in duplicate for the target mRNAs
and miR-185. The mean Ct values for the mRNA
targets were determined and normalized to
glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as endogenous controls while for
miR-185, small nuclear RNA (SNORD47) was
the endogenouse control. The qPCR primer
sequences are listed in table I. The relative
quantification was performed by 2(-ΔC𝑇 ): the
expression of target genes/housekeeping gene =
(1 + E) − C𝑇 target gene / (1 + E) − C𝑇 housekeeping
gene. The specificity of the PCR reactions was
verified by the generation of a melting curve
analysis followed by gel electrophoresis, visualized
by SafeView staining.
2.7. Standard curve and efficiency of
PCR
The qPCR efficiencies for each of the primer
pairs were derived from standard curves, which
were obtained from ten-fold serial dilutions of a
positive PCR product for VEGF-A and GAPDH by
a usual qRT-PCR. Logarithms of concentrations for
each dilution on the x axis were plotted against the
target gene-cycling threshold (Ct) of serial dilution
on the y axis. The VEGF-A and GAPDH efficiencies
were 91% and 95.9%, respectively.
Table I. Primer sequences for target and housekeeping genes
Gene and miRNA name NCBI ID Primer sequence 5’→3’ Productlength Cycle Ref
VEGF-A NM_001287044.1
F: AAATGCTTTCTCCGCTCTGA
R: CCCACTGAGGAGTCCAACAT 173 bp 40 Designed
PDGF NM_016205.3
F: GCCAGGTTGTCTCCTGGTTA
R: TGCTTGGGACACATTGACAT 86 bp 40 Designed
GAPDH NM_002046.7
F: TGCACCACCAACTGCTTAGC
R: GGCATGGACTGTGGTCATGAG 87 bp 40 Designed
SNORD47 NR_003014.2 F: ACT GTA AAA CCG TTC CA <100 bp 45 Designed
hsa-miR-185-5p MIMAT0000455 F: AGAGAAAGGCAGTTCC <100 bp 45 Designed
2.8. Ethical consideration
The study proposal was approved by
the ethics committee of Shahid Sadoughi
university of Medical Sciences, Yazd, Iran
(Code: IR.SSU.MEDICINE.REC.1395.300). Written
informed consent was obtained from all
participants.
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2.9. Statistical analysis
Statistical analysis was performed using
GraphPad Prism 6 (GraphPad software, San
Diego, California, USA). All the experiments were
performed at least twice. Using the 2−ΔΔCT
method, quantitative RT-PCR data were analyzed.
Data were expressed as mean ± SEM and the
results were scatter plots with a median value. For
statistical comparison between the study groups,
the two-tailed nonparametric Mann–Whitney
post-hoc and Kruskal–Wallis tests was used. The
receiver operating characteristic (ROC) curve was
obtained and the area under the curve (AUC) was
considered. Correlation analysis was performed
using a two-tailed Spearman’s rank correlation.
A p-value < 0.05 was considered as statistically
significant.
3. Results
Blood samples from 25 women with grade III-IV
endometriosis (case group) and 25 women without
endometriosis (control group) were screened
for the expression of circulating miR-185-5p,
VEGF, and PDGF target genes. The demographic
characteristics of our study participants are
presented in table II. As expected, the two
groups had significant differences in the terms of
body mass index (BMI) and cancer antigen 125
(p < 0.001). However, the groups did not show
significant differences in human epididymis protein
4, carcinoembryonic antigen, white blood cells or
hemoglobin (Table II).
For the evaluation of the quality (purity and
intactness) and quantity (concentration and
extraction efficiency) of extracted total RNA,
the NanoDrop ND-1000 and 1.5% agarose
gel electrophoresis were used (Figure1 a. The
RNA purity was measured using a NanoDrop
spectrophotometer, and the A260/A280 and
A260/A230 ratios were used as indicators of
different contaminants. Ratios between 1.8 and
2.0 for A260/A280 were accepted as indicating
pure RNA (Table III). Contamination by DNA and
protein was indicated by A260/A280 ratios above
2.0 or below 1.8. For the A260/A230 ratio, the
acceptance range was between 1.8 and 2.2 (Table
III).
The specificity of the qRT-PCR products of
the miR-185, target, and housekeeping genes
was confirmed by the existence of a unique
peak in the melting curve and the presence
of a single band with a predictable size after
agarose electrophoresis and SafeView nucleic acid
staining (Figure 1 a, b). To evaluate the miRNA
expression profiles in whole blood, total miRNAs
were isolated, and miRNA expression profiling
candidates were examined by Illumina-based deep
sequencing. A total of 856 mature miRNAs
were distinguished through small non-coding RNA
sequencing analysis. The expression profiles of 30
miRNAs were found to be significantly different
between the case and control groups (p<0.016). Of
these 30miRNAs, 15 were upregulated and 15were
downregulated with endometriosis (Figure 2). From
these miRNAs, the relative expression of miR-185-
5p in the whole blood and plasma of endometriosis
women is presented in Figure 3. On the other hand,
the expression level of miR-185-5p in plasma was
compared between the case and control groups
(Figure 3).
3.1. Plasma and whole blood
expression levels of miR-185-5p
3.1.1. Comparison of miR-185-5p
expression level in plasma and whole
blood
The expression levels of miR-185-5p in plasma
and whole blood were analyzed using qRT-PCR.
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The relative expression levels of candidate miRNA
are shown in Figure 3. Compared with the sera of
the control group, the expression of miR-185-5p in
the serum was significantly lower in the case group
(p < 0.001, RFC = 0.1469); however, no significant
change was observed in miR-185-5p expression in
whole blood from the cases compared with the
control group (p = 0.73, RFC = 1.43). Conversely,
plasma and whole blood levels of miR-185-5p were
different, and the expression level of miR-185-
5p in whole blood was significantly higher than
in sera in the case group (p < 0.001) (Figure
3). An ROC curve was generated to analyze the
capability of predicting endometriosis in women,
and the AUC of miR-185-5p was 0.919 (95%
confidence interval (CI): 0.808-1.029, specificity:
0.900, sensitivity: 0.812). The ROC curve analysis
of miR-185-5p is shown in Figure 4.
3.2. miR-185-5p as a potential
biomarker of endometriosis
To determine the potency of miR-185-5p
as a biomarker for endometriosis, an ROC
curve was plotted. Remarkably, ROC analysis
determined a cut-off value of 0.3750, with
high values for sensitivity, specificity, and the
AUC of 0.919 for miR-185-5p (P < 0.001; 95%
CI: 0.808-1.029), proposing it as a potentially
potent predictor for endometriosis (Figure
4).
3.3. Comparison of PDGF and VEGF
expression levels in whole blood
The evaluation of the gene targets of PDGF
and VEGF in whole blood showed no significant
difference in mRNA levels in the case group
compared with the controls. The results of
RT-PCR demonstrated that compared with the
controls, there was no significant decrease
or increase in the expression of VEGF and
PDGF mRNA in whole blood in the case
group compared to the control group (PDGF,
p = 0.0976 and VEGF, p = 0.3608). The
expression of VEGF-A and PDGF is therefore
not able to predict the clinical outcome (Figure
5).
Table II. Baseline characteristics of the case and the control groups
Characteristics Case group (n=25) Control group (n=25) P-value*
Age (years) 5.8 ± 31.3 5.4 ± 29.3 0.19
BMI (Kg/m2) 3.1 ± 21.8 5 ± 25.2 <0.001
CA125 (IU/ml) 45.2 ± 54.4 11.2 ± 17.3 <0.001
HE4 (pmol/l) 12.3 ± 47.6 10 ± 44.7 0.36
CEA (ng/ml) 0.6 ± 1.2 0.7 ± 1.4 0.40
WBC (count/μl) 1735 ± 6634 1662 ± 6948 0.49
Hb (g/dl) 1.3 ± 12.20 1.2 ± 12.90 0.14
All data were presented as Mean ± SD, BMI: Body mass index; CA125: Cancer antigen 125; HE4: Human epididymis protein 4;
CEA: Carcinoembryonic antigen; WBC: White blood cell; Hb: Hemoglobin, * Student’s t test
Table III. Total RNA and miRNA quantity and purity control using the NanoDrop Spectrophotometer
Sample Concentration (ng/μl) 260/280 ratio 260/230 ratio
Total RNA from whole blood (control group) 125.1 1.85 1.91
Total miRNA from whole blood (case group) 117.4 1.89 1.87
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A  
B  
Figure 1. A) Agarose gel (1.5%) presenting the amplification of a specific PCR product of the expected size for each gene tested in
this study. B) Specificity of real-time RT-PCR amplification after agarose gel electrophoresis. The melting curves of the miR-185-5p,
PDGF, VEGF, and housekeeping genes including SNORD47 and GAPDH show a single pick.
Figure 2. Volcano plot of miRNA analysis showing the aberrant expression of miRNAs in whole blood from women with and
without endometriosis. A. Plots of log2 fold-change (FC) plot vs. average counts (AC) for differentially expressed miRNAs. The AC
represents different miRNA expression between two study groups. The red lines indicate |log2 FC| = 1. B. Plots of log2 FC plot on
p (significance level). The purple dots represent significant upregulated miRNA (|log2 FC| > 1, p < 0.015), the green dots represent
significant downregulated miRNA (|log2 FC| > 2, p < 0.017), and the black dots represent no significance.
https://doi.org/10.18502/ijrm.v13i5.7155 Page 353
International Journal of Reproductive BioMedicine Razi et al.
Figure 3.Quantitative real-time PCR analysis of miR-185-5p in whole blood and plasma in the case group compared to the controls
(n = 25, pooled sample). The results are normalized relative to the expression level of the reference gene, SNORD47. Lines are
drawn to demonstrate the median value, and the Mann-Whitney U test was used to calculate statistical significance (** p < 0.01,
nonparametric Mann-Whitney test).
Figure 4. ROC curve analysis of miR-185 for endometriosis sample set analyzed for relative expression level of miR-185-5p in
plasma. Best cut-off = 0.3750, sensitivity = 0.812, specificity = 0.900, 1-specifiity = 0.1, AUC = 0.919 (p < 0.001; 95% CI: 0.808-
1.029).
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Figure 5. Quantitative real-time PCR analysis of PDGF and VEGF for whole blood of the case group (n = 25, pooled sample)
compared to the controls (n = 25, pooled sample). The results are normalized relative to the expression level of the reference
gene, GAPDH. Lines are drawn to demonstrate the median values, and the Mann-Whitney U test was used to calculate statistical
significance.
4. Discussion
The present study was undertaken to elucidate
the expression level of miR-185-5p in the plasma
and whole blood and its angiogenesis-related
potential targets (VEGF and PDGF) in the whole
blood of 25 women with endometriosis compared
with the 25 women without endometriosis. A
differential expression analysis of circulating
miR-185-5p was conducted and predicted their
downstream VEGF and PDGF target genes among
the case and control groups using real-time
quantitative RT-PCR to provide evidence of the
value of miR-185-5p as a new diagnostic biomarker
for endometriosis. The goal was to enhance the
understanding of the gene expression pattern
of miR-185-5p in plasma and whole blood and
to assess the potency of this as a biomarker of
disease progression in endometriosis.
The results showed that there was a lower
expression of miR-185-5p in the plasma of the
case group compared to the controls (Figure 3)
and that there was no significant difference in the
expression of VEGF and PDGF mRNA of whole
blood in endometriosis patients compared to the
control group (Figure 5). The results show that the
mRNA expressions of VEGF and PDGF in whole
blood were not statistically significant between
the endometriosis and control groups (Figure 5),
although increases of 3.12 (PDGF) and 2.33 (VEGF)
in relative fold change were observed in the case
groups.
To date, few studies have focused on the
expression of VEGF and PDGF simultaneously
in the whole blood of women suffering from
endometriosis. Previous research findings relating
to the gene expression pattern of VEGF and PDGF
have been inconsistent and contradictory (19-22).
The gene expression result of VEGF is similar to
the results of Pellicer and colleagues who could
not find a significant alternation in the mRNA
expression of interleukin-1𝛽 and VEGF in women
with endometriosis (23). Inconsistent results
were identified regarding the gene expression
and polymorphisms in the VEGF gene in the
progression of endometriosis, which can be
ascribed to methodological differences, sample
size, qualified control type, using unadjusted risk
estimates, and the heterogeneity of the people
studied. In some studies, the serum level of the
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VEGF marker in endometriosis was found to be
different from our recent results (24, 25). Some
studies have shown an increase in the VEGF
expression level and a significant difference in
patients with endometriosis compared to the
control group (26, 27). In another study, the
VEGF level in different phases of the menstrual
cycle (in patients who were assumed to have
endometriosis) was compared with control groups,
and no statistical difference was identified after
the calculation of the phase of the cycle (28).
One of the advantages of our data was the
simultaneous comparison of VEGF and PDGF
expression in whole blood in women with
endometriosis compared with the control group.
Blood is a tissue and is made up of a variety of
cells, each having a different job. In our study, we
used whole blood for RNA extraction and miRNA
profiling and gene expression quantification of
target genes. The buffy coat compose less than 1%
of the total volume of the blood, but most of the
white blood cells and platelets aggregate in it and
therefore it is a good source for RNA extraction.
Plasma is considered as an acellular blood
component; therefore, nucleic acids extracted
from whole blood are mainly extracted from
peripheral blood mononuclear cells, including T
cells, B cells, NK cells and monocytes (29).
As previously mentioned, PDGF is a platelet-
derived growth factor that is an effective mitogen
and plays a critical role in the inflammatory
response and in the proliferation and differentiation
of progenitor cells. It has been confirmed
that PDGF plays an essential role in several
physiological processes such as wound healing,
regeneration, cell proliferation, migration, and
angiogenesis. It was reported that PDGF induced
the differentiation of embryonic stem cells into
endothelial cells (30) and it was indicated that
PDGF is also involved in vascular development
and tumor angiogenesis in pathological conditions
(9, 31). In concert with other proangiogenic factors,
PDGF induces the formation and spread of new
vessels by recruitment of perivascular cells.
It is said that overexpression of PDGF along
with VEGF results in pericyte vessel formation
and angiogenesis (32). It is also said that
combined blockage of VEGF, FGF and PDGF
cell signaling pathways suppresses angiogenesis
in endometriosis lesions (33).
In our study, despite the expression of PDGF
and VEGF being elevated in the whole blood of
women with endometriosis, the increased mRNA
levels of PDGF and VEGF were not statistically
significant. This statistical insignificance could be
the result of the small sample size; seemingly
insignificant population differences might still find
statistical significance. A larger and more varied
population would lead to more meaningful results.
Based on the above-mentioned reports, it might
be anticipated that other miRNAs that target PDGF
and VEGF and their receptors could describe
molecular and cellular features of endometriotic
lesions with a focus on the VEGF- and PDGF-
signaling pathways.
According to the previous studies, it appears
that angiogenic activity may be increased by the
raised level of VEGF in the peritoneal fluid of
endometriosis patients. These elevated levels of
VEGF and PDGF possibly trigger proangiogenic
mediator secretion and neovascularization within
the peritoneal environment.
It seems that endometriosis is only related
to pelvic inflammation and has nothing to do
with the change of VEGF and PDGF levels in
circulation. The current knowledge of specific
miRNAs that regulate the PDGF and VEGF signal
pathways favors the idea that this might be a
remunerative target for the development of novel
therapeutics. Considering that the subjects in this
study had different types of clinical profile that
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could change the level of VEGF and PDGF in
the blood in both the endometriosis and control
groups, it can be said that the lack of significant
difference observed in VEGF and PDGF could
be due to these specific cases. Furthermore, the
difference in these controversial results may be
due to the small number of people involved in the
study.
To avoid any difference in the results, fertile
women free of gynecological diseases should be
used to form an ideal control group. However,
multi-centric studies with a suitable design
involving different populations, together with
the combined analysis of gene expression in
VEGF and PDGF, are necessary to contribute to
the understanding of this disease. Nonetheless,
the results of the ROC analysis of miR-185-5p
expression suggest a potentially non-invasive
biomarker in the plasma of endometriosis patients
that could reflect disease progression (Figure
4). Therefore, miR-185-5p could potentially serve
as a diagnostic biomarker in the prognosis and
diagnosis of endometriosis and for evaluation
of therapeutic strategies for endometriosis at
the molecular level. This will require further and
larger-scale studies for confirmation.
5. Conclusion
Our findings proposed miR-185-5p as a novel
biomarker and regulator in endometriosis
pathogenesis, and these findings support the
notion that target therapies against miR-185-5p
should have priority in targeting PDGF and VEGF.
They are therefore promising tools in therapeutic
developments to control the progression and
metastasis processes in endometriosis patients.
Overall, the results of the statistical analysis
suggest miR-185-5p as a potential biomarker of
disease activity in endometriosis.
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